Cogent Biosciences, Inc. (COGT) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−14.9x

Market Cap

$6.02B

MomentumView details →

1D Return

−0.68%

YTD Return

−2.66%

RSI (14)

38.1

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−14.9x

Market Cap

$6.02B

RSI (14)

38.1

MomentumView details →

1D Return

−0.68%

YTD Return

−2.66%

SummaryUpdated Jun 1, 2026

Cogent Biosciences, Inc. (NASDAQ:COGT) is a biotechnology company founded in 2014 and headquartered in Cambridge, Massachusetts. Originally incorporated as Unum Therapeutics Inc., the company underwent a strategic transformation and rebranded to Cogent Biosciences in October 2020. The company went public in March 2018 and focuses on developing precision therapies for genetically defined diseases, particularly targeting rare conditions with significant unmet medical needs.

Ask drillr about Cogent Biosciences, Inc. →

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−70.85%

ROA (TTM)

−45.20%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+4.55%

FCF YoY

−31.79%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+12.07%

EBITDA YoY

−28.64%

EarningsView details →

EPS (Actual)

−$0.52

EPS Surprise

6.30%

Beats (12Q)

3/12

Next Q EPS Est

−$0.55

Avg Surprise (4Q)

1.47%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.46x

Current Ratio

13.57x

Quick Ratio

13.57x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−377.18M

Op. CF (TTM)

−307.55M

Next earningsNov 6, 2026 →

Latest newsMore news →

Cogent Biosciences signed a five-year commercial supply agreement with Hovione FarmaCiencia S.A. for the purchase of bezuclastinib spray-dried dispersion and tablets, with automatic two-year renewals.2d ago

Cogent Biosciences reported a net loss of $96.4 million for Q2 2026, with research and development expenses of $70.8 million and general and administrative expenses of $31.8 million.26d ago

Similar companies

科前生物688526.SH Dianthus Therapeutics, Inc.DNTH 悦康药业688658.SH Kiniksa Pharmaceuticals, Ltd.KNSA Terns Pharmaceuticals, Inc.TERN Liquidia CorporationLQDA Find similar companies →

Latest newsMore news →

Cogent Biosciences signed a five-year commercial supply agreement with Hovione FarmaCiencia S.A. for the purchase of bezuclastinib spray-dried dispersion and tablets, with automatic two-year renewals.2d ago Cogent Biosciences reported a net loss of $96.4 million for Q2 2026, with research and development expenses of $70.8 million and general and administrative expenses of $31.8 million.26d ago